Dr. J. Strains & sprains
Natural health product licensed in Canada
- Other names
- Back Pain & Arthritis
- Licence holder
- Holy Land Traditional Medications Inc.
- NPN or DIN-HM
- 80076713
- Status
- Active licence
- Licence date
- 13 April 2017
- Revision date
- Not provided
- Form
- Crème
- Route of administration
- Topique
- Application type
- Officinale
Oral dose analysis does not apply without an established exclusively oral route.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source |
|---|---|
| 1,3,3-triméthyl-2-oxabicyclo(2.2.2)octane Source : Eucalyptol | 0.5 Pour cent |
| dl-Camphre Source : dl-Camphre | 1 Pour cent |
| 1-méthyl-3-hydroxy-4-isopropylbenzène Source : Thymol | 0.5 Pour cent |
Non-medicinal ingredients
Palmitate d'isopropyle, Huile de jojoba, Cétéareth-25, Acide stéarique, Caprylyl glycol, Huile minérale, PPG-17, Phénoxyéthanol
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes et adolescents | minimum: 2 years | 1 Crème | minimum: 3 Tous les jours ; maximum: 4 Tous les jours |
Uses authorised in Canada
Temporarily relieves aches and pains of muscles and joints associated with one or more of: Simple backache, lumbago, strains and sprains (involving muscles, tendons, and/or ligaments), and arthritis.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Précautions et mises en garde
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a Poison Control Center immediately. If symptoms persist and/or worsen after 7 days or re-occur within a few days, discontinue use and consult a health care practitioner. If you are pregnant or breastfeeding, consult a health care practitioner prior to use. To mitigate the potential risk to the health of children, child-resistant packaging/containers should be used for.
- Effets indésirables connus
Rashes and/or burning discomfort have been known to occur; in which case, discontinue use. Hypersensitivity has been known to occur; in which case, discontinue use.
Source
Official Health Canada record, licence 80076713
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.